null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, funded primarily by equity raises; near-zero leverage ratio

Low direct sensitivity; no significant floating-rate debt, but higher rates increase cost of future equity/debt capital raises

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese API/CRO manufacturing concentration; 2) Single-source specialty reagent suppliers for covalent inhibitor synthesis

No meaningful international revenue; pre-commercial stage, so sovereign currency devaluation exposure is negligible

Operations centered in Boulder, CO; no international revenue markets; currency devaluation exposure effectively zero

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on select CROs (e.g., WuXi AppTec or peers) for synthesis and IND-enabling studies; likely >30% operational input concentration

Clinical-stage drug discovery biotech; no cloud-dependent commercial product; account termination would disrupt R&D ops but not destroy revenue

Secondary impact: loss of computational chemistry and data management infrastructure would delay pipeline timelines by estimated 3–6 months

Moderate API coupling to specialized CRO platforms; switching feasible but costly in time (6–12 months) and regulatory revalidation burden

Low Howey risk; revenue model is milestone/royalty licensing from drug assets, not investment contracts; equity is standard securities

Very High

Minimal GDPR/CCPA exposure; no consumer data collected; clinical trial data governed by FDA/ICH GCP, not consumer privacy frameworks

Negligible; small-cap pre-commercial biotech with no market dominance; standard pharma licensing poses no meaningful antitrust risk

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

100% transactional/milestone-based; no recurring subscription revenue; dependent on partnership deals and future royalties

Licensing deals, research collaborations, and eventual royalties on approved drugs; no SaaS or subscription component

No commercial pricing yet; future drug pricing will face payer/PBM negotiation pressure typical of oncology therapeutics

Moderate-to-high potential if covalent KRASG12C or related assets achieve best-in-class differentiation; subject to competitive ADC/inhibitor landscape

Biotech royalty/licensing model targets 85–95% gross margin at commercial stage; current stage shows no product gross margin

No free-rider risk; IP-protected drug assets with patent moats; academic publication risk is real but manageable via trade secrets

Headcount-linear at current stage; R&D-intensive org where doubling pipeline programs requires proportional scientific staff increases

Sublinear at commercial stage (future royalties scale without headcount); currently linear due to lab-bench discovery model

Not applicable; OnKure is not a franchise business

At 10x scale (multiple licensed programs), partnership CAC becomes negligible relative to milestone value; BD team cost is key leverage point

No traditional network effects; scientific platform credibility compounds over time but is not a true demand-side network effect

-124.6% Return on Assets (Negative equity)

Moderate resilience; oncology drug development funding can compress in deep recessions but remains priority vs. elective therapeutic areas

Large pharmaceutical and biotech companies seeking covalent inhibitor pipeline via licensing or co-development agreements

Government/NIH grants and academic collaborators supplementing early-stage discovery funding

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated to future-state R&D infrastructure (lab build-out, IND-enabling studies); no legacy infrastructure drag; burn-funded by equity

0001637715

OKUR